Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 18, 2014

View Archived Issues

Development of non-viral minicircle DNA vectors for phenylketonuria gene therapy

Auigene Discovery Technologies and UM Pharmauji report DHODH inhibitors

AAK1 inhibitors disclosed in recent BMS patent

Long-term treatment with fingolimod sustains low rates of brain volume loss in LONGTERMS trial

Immunotope licenses CaPtivate's nanoparticle technology for T-cell vaccines

OncoCyte to use Abcodia's serum bank to validate its PanC-Dx cancer diagnostic

BARDA contract supports InDevR's development of FluChip-8G influenza diagnostic

MGB Biopharma raises funding for phase I trial of novel antibacterial MGB-BP-3

ASP-2397, a natural product with potent fungicidal activity

TapImmune reports interim data from phase I trial of folate receptor alpha antigens

FDA assigns orphan drug designation to various cancer therapies under development

Novel potent inhibitors of histone demethylase KDM1A for epigenetic-related cancer therapy

Oncolytics reports progression-free survival data from trial of Reolysin in pancreatic cancer

In vitro and in vivo bone anabolic effects of P2X7 receptor blocker AFC-5261

Alnylam Pharmaceuticals describes siRNA for treating pre-eclampsia

Empagliflozin/linagliptin FDC shows superior efficacy to individual components

Akashi Therapeutics acquires worldwide rights to GsMTx-4

Concert Pharmaceuticals begins phase I trial of CTP-730

Sun Pharma and Merck & Co. form licensing agreement for tildrakizumab

Prezcobix launched in Canada for HIV

Otsuka Pharmaceutical receives approval for BCR-ABL mRNA measurement kit

Parion Sciences receives award from Cystic Fibrosis Foundation Therapeutics

CTI BioPharma and Servier to develop and commercialize Pixuvri

NicOx to acquire French ophthalmic company Doliage

BioBlast Pharma reports data from several studies of Cabaletta

FDA places clinical hold on phase IIb study of Flexion's FX-006 for knee osteoarthritis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...